Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Ohe, Y. Ohashi, K. Kubota, T. Tamura, K. Nakagawa, S. Negoro, Y. Nishiwaki, N. Saijo, Y. Ariyoshi, M. Fukuoka (2006)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.Annals of oncology : official journal of the European Society for Medical Oncology, 18 2
Chih‐Hsin Yang, L. Simms, Keunchil Park, Jin-Soo Lee, G. Scagliotti, M. Orlando (2010)
Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III TrialJournal of Thoracic Oncology, 5
T. Kimura, H. Taniguchi, Naohiro Watanabe, H. Saka, Y. Kogure, J. Shindo, T. Ogasawara, E. Kojima, Y. Hasegawa, Masashi Yamamoto, R. Suzuki, M. Ando, M. Kondo, H. Saito (2016)
Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.Anticancer research, 36 4
A. Ilhan-Mutlu, M. Osswald, Yunxiang Liao, M. Gömmel, M. Reck, D. Miles, P. Mariani, L. Gianni, B. Lutiger, V. Nendel, S. Srock, P. Perez-Moreno, F. Thorsen, Louisa Baumgarten, M. Preusser, W. Wick, F. Winkler (2016)
Bevacizumab Prevents Brain Metastases Formation in Lung AdenocarcinomaMolecular Cancer Therapeutics, 15
L. Paz-Ares, F. Marinis, M. Dediu, Michael Thomas, J. Pujol, P. Bidoli, O. Molinier, T. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli (2013)
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 23
T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, Takashi Takahashi, T. Mitsudomi (2004)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 64
S. Niho, H. Kunitoh, H. Nokihara, T. Horai, Y. Ichinose, T. Hida, N. Yamamoto, M. Kawahara, T. Shinkai, K. Nakagawa, K. Matsui, S. Negoro, A. Yokoyama, S. Kudoh, K. Kiura, K. Mori, H. Okamoto, H. Sakai, K. Takeda, S. Yokota, N. Saijo, M. Fukuoka (2012)
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.Lung cancer, 76 3
A. Cardona, L. Rojas, B. Wills, O. Arrieta, H. Carranza, C. Vargas, J. Otero, M. Cuello, L. Corrales, C. Martin, C. Ortíz, S. Franco, R. Rosell (2016)
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase ExpressionPLoS ONE, 11
Caicun Zhou, Yi-long Wu, Gongyan Chen, Xiaoqing Liu, Yunzhong Zhu, Shun Lu, Jifeng Feng, Jianxing He, B. Han, Jie Wang, G. Jiang, Chunhong Hu, H. Zhang, G. Cheng, Xia Song, You Lu, H. Pan, W. Zheng, A. Yin (2015)
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 19
A. Rossi, S. Ricciardi, P. Maione, F. Marinis, C. Gridelli (2009)
Pemetrexed in the treatment of advanced non-squamous lung cancer.Lung cancer, 66 2
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David Johnson (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.The New England journal of medicine, 355 24
M. Reck, J. Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold (2009)
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
F. Barlesi, A. Scherpereel, V. Gorbunova, R. Gervais, A. Vikström, C. Chouaid, A. Chella, Jeong-Ho Kim, M. Ahn, Martin Reck, A. Pazzola, H. Kim, J. Aerts, Claire Morando, A. Loundou, H. Groen, A. Rittmeyer (2014)
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology, 25 5
Jong-Mu Sun, J. Ahn, Sin-Ho Jung, Jiyu Sun, S. Ha, Joungho Han, Keunchil Park, M. Ahn (2015)
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 22
R. Siegel, K. Miller, A. Jemal (2017)
Cancer statistics, 2017CA: A Cancer Journal for Clinicians, 67
H. Kimura, N. Yamamoto, T. Shirai, H. Nishida, K. Hayashi, Y. Tanzawa, A. Takeuchi, S. Miwa, H. Tsuchiya (2016)
Clinical Outcome of Reconstruction Using Frozen Autograft for a Humeral Bone Tumor.Anticancer research, 36 12
T. Yokoi, Yoshitaro Torii, Y. Katashiba, Hiroyuki Sugimoto, Tsutomu Tanijiri, Makoto Ogata, N. Inagaki, K. Kibata, M. Hayashi, Maiko Niki, Toshiki Shimizu, T. Miyara, T. Kurata, S. Nomura (2014)
Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancerOncology Letters, 8
Yan Fu, Jia Hu, N. Du, S. Jiao, Fang Li, Xiaosong Li, Junxun Ma, Hui Zhao, Huanrong Kang (2016)
Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancerJournal of Chemotherapy, 28
Nobuyuki Ishikura, M. Yanagisawa, Mariko Noguchi-Sasaki, T. Iwai, K. Yorozu, M. Kurasawa, Masamichi Sugimoto, Kaname Yamamoto (2017)
Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.Anticancer research, 37 2
Tony Mok, Yi-Long Wu, S. Thongprasert, Chih-Hsin Yang, Da-Tong Chu, N. Saijo, P. Sunpaweravong, Baohui Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, Jin-Ji Yang, B. Chewaskulyong, Haiyi Jiang, E. Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka (2009)
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.The New England journal of medicine, 361 10
K. Yoh, Y. Goto, Y. Naito, K. Kishi, K. Mori, K. Hotta, Y. Hosomi, Kazuhiko Yamada, C. Tanai, Y. Tomizawa, A. Inoue, Y. Hasegawa, M. Nishio, Y. Ohashi, H. Kunitoh (2017)
Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.Anticancer research, 37 3
F. Barlesi, A. Scherpereel, A. Rittmeyer, A. Pazzola, Neus Tur, Joo‐Hang Kim, M. Ahn, J. Aerts, V. Gorbunova, A. Vikström, E. Wong, P. Perez-Moreno, L. Mitchell, H. Groen (2013)
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 24
T. Mok, T. Hsia, C. Tsai, K. Tsang, G. Chang, J. Chang, Sirisinha Thitiya, V. Sriuranpong, S. Thongprasert, D. Chua, N. Moore, C. Manegold (2011)
Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trialAsia‐Pacific Journal of Clinical Oncology, 7
Shang-Gin Wu, Chih‐Hsin Yang, Chong-Jen Yu, Jih-hsiang Lee, Y-C Hsu, Yih-Leong Chang, J. Shih, Pan‐Chyr Yang (2011)
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations.Lung cancer, 72 3
D. Gandara, T. Kawaguchi, J. Crowley, J. Moon, K. Furuse, M. Kawahara, S. Teramukai, Y. Ohe, K. Kubota, S. Williamson, O. Gautschi, H. Lenz, H. McLeod, P. Lara, C. Coltman, M. Fukuoka, N. Saijo, M. Fukushima, P. Mack (2009)
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 21
G. Scagliotti, P. Parikh, J. Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J. Lee, A. Mellemgaard, Keunchil Park, S. Patil, J. Rolski, T. Goksel, F. Marinis, L. Simms, K. Sugarman, D. Gandara (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
Lei Wang, Rui Wang, Yunjian Pan, Yihua Sun, Jie Zhang, Haiquan Chen (2014)
The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysisBMC Cancer, 14
国立がん研究センターがん対策情報センター (2011)
The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2005: Based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project, 41
T. Matsuda, T. Marugame, K. Kamo, K. Katanoda, W. Ajiki, T. Sobue (2011)
Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project.Japanese journal of clinical oncology, 41 1
O. Gautschi, S. Rothschild, Qiyu Li, K. Matter-Walstra, A. Zippelius, D. Betticher, M. Früh, R. Stahel, R. Cathomas, D. Rauch, M. Pless, S. Peters, P. Froesch, T. Zander, M. Schneider, C. Biaggi, N. Mach, A. Ochsenbein (2017)
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small‐cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialClinical Lung Cancer, 18
Weiyou Zhu, O. Røe, Chen Wu, Wei Li, R. Guo, Yanhong Gu, Yi-qian Liu, Y. Shu, Xiaofeng Chen (2015)
Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective studyJournal of Chemotherapy, 27
I. Okamoto, K. Aoe, T. Kato, Y. Hosomi, A. Yokoyama, F. Imamura, K. Kiura, T. Hirashima, M. Nishio, N. Nogami, H. Okamoto, H. Saka, N. Yamamoto, N. Yoshizuka, R. Sekiguchi, K. Kiyosawa, K. Nakagawa, T. Tamura (2013)
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancerInvestigational New Drugs, 31
B. Besse, S. Moulec, J. Mazières, H. Sénellart, F. Barlesi, C. Chouaid, É. Dansin, H. Bérard, L. Falchero, R. Gervais, G. Robinet, A. Ruppert, R. Schott, H. Léna, C. Clément‐Duchêne, X. Quantin, P. Souquet, J. Trédaniel, D. Moro-Sibilot, M. Pérol, A. Madroszyk, J. Soria (2015)
Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II StudyClinical Cancer Research, 21
B. Chan, B. Hughes (2015)
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Translational lung cancer research, 4 1
Purpose This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/ kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non- squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor receptor (EGFR)-wild type. Patients and methods Fifty patients with advanced or metastatic EGFR-wild type NSCLC aged < 75 years old were enrolled 2 2 in the study. The patients were treated with four cycles of cisplatin (75 mg/m , day 1), pemetrexed (500 mg/m , days 1), and bevacizumab (15 mg/kg, day 1), every 3 weeks, followed by pemetrexed plus bevacizumab maintenance until progression for achieving a response over stable disease after induction chemotherapy. Results Partial response and stable disease were observed in 35 (objective response rate: 70, 95% CI: 55.4–82.1%) and 9 patients, respectively, and 39 (78%) patients received pemetrexed plus bevacizumab maintenance therapy. Median progres- sion-free survival and overall survival periods were 12.0 months (95% CI: 7.5–16.5 months) and 31.0 months (95% CI: 22.2–39.8 months), respectively. Grade 3 adverse events included neutropenia (14%), nausea (10%), anorexia (18%), and hypertension (8%). Coagulation disorder was observed in one patient, but all of these events were reversible and resulted in no
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Apr 11, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.